



PHILIP MORRIS INTERNATIONAL

## PRESS RELEASE

Investor Relations:  
Stamford, CT: +1 (203) 904 2410  
Lausanne: +41 (0)58 242 4666  
Email: [InvestorRelations@pmi.com](mailto:InvestorRelations@pmi.com)

Media: David Fraser  
Lausanne: +41 (0)58 242 4500  
Email: [David.Fraser@pmi.com](mailto:David.Fraser@pmi.com)

### **Philip Morris International to Host Webcast of Fireside Chat Session at Barclays Global Consumer Staples Conference**

STAMFORD, CT – August 26, 2025 – Philip Morris International Inc. (PMI) (NYSE: PM) will host a live webcast of a fireside chat session with Jacek Olczak, Chief Executive Officer, at the 2025 Barclays Global Consumer Staples Conference at [www.pmi.com/2025barclays](http://www.pmi.com/2025barclays) on Tuesday, September 2, 2025, at approximately 11:15 a.m. ET. An archived copy of the webcast will be available for six months post-event.

The webcast may also be accessed on mobile devices by downloading PMI's free Investor Relations Mobile App at [www.pmi.com/irapp](http://www.pmi.com/irapp).

#### **Philip Morris International: A Global Smoke-Free Champion**

Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. As of June 30, 2025, our smoke-free products were available for sale in 97 markets, and PMI estimates they were used by over 41 million legal-age consumers around the world, many of whom have moved away from cigarettes or significantly reduced their consumption. The smoke-free business accounted for 41% of PMI's first-half 2025 total net revenues. Since 2008, PMI has invested over \$14 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match's *General* snus and ZYN nicotine pouches and versions of PMI's IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables and *General* snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness and healthcare areas and aims to enhance life through the delivery of seamless health experiences. References to "PMI", "we", "our" and "us" mean Philip Morris International Inc., and its subsidiaries. For more information, please visit [www.pmi.com](http://www.pmi.com) and [www.pmiscience.com](http://www.pmiscience.com).